Skip to main content

etigilimab

·Code: OMP-313M32

etigilimab: sourced relationships with 2 companies.

etigilimab evidence translation

What we can confirm

No verified FDA or trial count is available.

What it means

More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Evidence is limited; missing information remains unknown.
BioSniper AIPage evidence connected

Prepared research question

What is verified about etigilimab, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Related indications

Solid tumor typesAdvanced or metastatic solid tumors

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (2)
CompanyDated record stage
Mereo BioPharma Group plc (MREO)
developer · Reported 2024-03-27 · Current development: unknownSource
Solid tumor types
Phase 1
OncoMed Pharmaceuticals Inc (OMED)
licensee · Reported 2019-03-07 · Current development: unknownSource
Advanced or metastatic solid tumors
Phase 1